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grams compare favorably with the prevented potential ther-
apeutic costs of late-stage melanoma. The low response rate 
of screenees agreeing to be followed up limits conclusions 
of this study.  © 2017 S. Karger AG, Basel 
 Introduction 
 Switzerland has the highest incidence of melanoma in 
Europe and a long tradition in participating in skin can-
cer prevention campaigns. Since 2001, a National Skin 
Cancer Screening Day has been organized by the Swiss 
Society of Dermatology and Venereology on a yearly ba-
sis. In order to enhance its impact, the campaign was ac-
companied by intense media coverage and other activities 
such as public seminars. On this particular day, partici-
pating dermatologists (both in private practice and hos-
pitals) offered free skin cancer screening examinations. 
The campaign was performed as a collaboration of the 
Swiss Society for Dermatology and Venereology, the Eu-
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 Abstract 
 Background: Skin cancer prevention and screening pro-
grams are performed in many countries. Their benefit is dis-
cussed controversially.  Objective: Our aim is to evaluate the 
Skin Cancer Screening Program 2013 in Switzerland by fol-
lowing up screenees upon interventions.  Methods: Quality 
was assessed by personal follow-up via phone/e-mail of ev-
ery patient that had been screened during this campaign 
and histological follow-up of all participants with suspicious 
skin lesions.  Results: Of the 1,087 screenees requiring inter-
ventions, 263 agreed to participate in the follow-up. We 
were able to obtain 66 histology reports. During this cam-
paign 33 malignant lesions (8 melanomas) were removed. 
 Conclusion: The overall melanoma detection rate in our free 
Skin Cancer Screening Program is comparable to those in 
European public activities. The costs of free screening pro-
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romelanoma Initiative, and the Swiss Cancer League. In 
2013, 86 dermatologists (in private practice and 5 univer-
sity hospitals) participated in this campaign. The partici-
pants were free to decide whether they wanted to see the 
patients based on appointments or whether the patients 
could present themselves at their practice without an 
appointment (open house consultations). During the 
screening, clinical total body examination and dermos-
copy of suspect lesions were performed. All participating 
dermatologists were volunteers and were seeing patients 
free of charge. The objective of this study was to evaluate 
the Skin Cancer Screening Program 2013 in Switzerland 
by following up screenees upon interventions.
 Methods 
 For further details, see the online supplementary material (see 
www.karger.com/doi/10.1159/000484946 for all online suppl. ma-
terial) ( Fig. 1 ).
 Results 
 In 2013, 86 dermatologists (in private practice and 5 
university hospitals) participated in this campaign. All 
geographic and 4 language regions of Switzerland were 
represented. The complete workflow is shown in  Figure 
1 . A total of 2,782 questionnaires were collected. Out of 
all the patients who were seen during this campaign, 
1,695 (60.9%) required no further action. In 1,087 pa-
tients, the physician performing the screening examina-
tion recommended either a control visit ( n = 685, 24.6% 
of 2,782 screens) or a biopsy/excision ( n = 402, 14.5%). Of 
these 1,087 patients, 804 (73.9%) did not agree to be con-
tacted 6 months later for the purpose of quality assess-
ment; 283 patients agreed to be contacted and provided 
anonymous contact details (phone number or e-mail ad-
dress). Of these 283 patients who agreed to participate, we 
were able to contact 188 of them after 6 months. In 5 
cases the contact information was not correct (i.e., phone 
number not working or incorrect e-mail address), and in 
90 cases the patients did not reply (39 by phone, 51 by 
e-mail). Of the 188 remaining patients, 31 (16.5%) stated 
not to have followed the recommendations from the 
screening visit (control or biopsy), and 41 (21.8%) had a 
control visit as proposed, but there was no further treat-
ment required. Of the remaining 116 patients, 15 an-
swered that a biopsy was performed, but they did not 
agree to communicate the results. 
All volunteers
n = 2,782
No
n = 1,695Control/biopsy
Yes
n = 1,087
Agreed to
participate
No
n = 804
Yes
n = 283
Contact possible Non = 95
Yes
n = 188
Control/biopsy
done
No
n = 31
Yes
n = 157
Biopsy Non = 41
Yes
n = 116
Consent to
access results
No
n = 15
Yes
n = 101
Path report
received
No
n = 35
Yes
n = 66
 Fig. 1. Flowchart of Methods. Workflow follow-up of participants 
of the Swiss Melanoma Day 2013. 
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 We ended up with 101 patients with an excision agree-
ing to communicate the results. Of these 101 patients, we 
were able to get an anonymized copy of their pathology 
report in 66 cases. In the remaining 35 cases we were not 
able to access this information even though the patients 
had agreed to share this information with us and they had 
contacted their physicians.
 Analysis of the 66 evaluable cases revealed the follow-
ing diagnoses: 8 melanomas, 17 basal cell carcinomas, 4 
squamous cell carcinomas, 4 malignant skin tumors of 
other type, 11 dysplastic nevi, and 5 actinic keratosis ( Ta-
ble 1 ). Dysplastic nevi in our definition are lesions which 
clinically and dermoscopically look atypical but which 
lack histological hallmarks of melanoma. Detailed infor-
mation regarding the 8 melanomas can be found in  Ta-
ble 2 . The average tumor thickness was 1.02 mm (median 
0.65; range 0.42–3.3).
 The description of the epidemiological data is based on 
the 283 patients who required follow-up or biopsy and 
who agreed to participate in this anonymous evaluation. 
The majority of participants were females (54.8%) aged 
between 50 and 75 years (50.5%). The average/median 
ages were 62/66 years for male and 53/56 years for female 
participants. The majority lived in a partnership (70.3%). 
Overall, 70.3% came for prevention and 25.4% because 
they were concerned about a specific lesion; 12% (7/66) 
had more than 100 nevi, and 2 of the 8 melanoma patients 
were among this group (25%). The predominant skin 
type was type 2 (30.4%). The results of the epidemiologi-
cal data are summarized in  Table 3 .
 A total of 48 of the 66 participants (72.7%) who re-
quired an excision/biopsy came for prevention reasons 
only. They were not concerned about a specific lesion 
themselves. In the group of histologically proven melano-
mas, this was the case for 4 out of 8 patients (50%), indi-
cating that half of the participants diagnosed with mela-
noma did not suspect this at all when they attended for 
screening.
 In our series, the positive predictive value for mela-
noma, i.e., the ratio of true positives (melanoma) and pos-
itive calls (dermoscopic suspicion) was 8/11 (0.73). The 
detection rate for melanoma in the entire test set was 
8/2,782 screenees, resulting in a detection rate of 0.29%. 
 Discussion 
 We have analyzed the data of 66 fully assessed screenees 
of our Annual Skin Cancer Prevention Day. If we extrap-
olate the results of the 66 patients with full analysis to the 
 Table 1.  Distribution of the diagnoses of the 66 histologies we were 
able to track down, as well as the estimates for all 402 performed 
biopsies
Diagnosis Distribution
(n = 66)
Estimate 
(n = 402)
Benign
Benign nevi
12 73
Seborrheic keratosis 5 30
Actinic keratosis 5 30
Dysplastic nevi 11 67
Total benign 33 201
Malignant
Melanoma
8 49
Basal cell carcinoma 17 104
Squamous cell carcinoma 4 24
Other 4 24
Total malignant 33 201
Total 66 402
 Table 2.  Subtypes of the histologically proven melanomas with tu-
mor thickness (n = 8)
Melanoma subtype Thickness, mm
Lentigo maligna melanoma 0.6
Spitzoid malignant melanoma 0.7
Superficial spreading melanoma 0.42
Malignant melanoma 3.3
Superficial spreading melanoma 1.39
Nodular malignant melanoma 1.41
Melanoma in situ 0
Superficial spreading melanoma 0.35
The average thickness was 1.02 mm (median 0.65).
 Table 3.  Reasons for participation in skin cancer screening among 
all proven biopsy cases versus all histologically proven melanoma 
cases
Reason for screening Proven 
biopsies
Proven 
melanomas 
Prevention 48 4
Patient concern 8 1
History of skin cancer 1 1
Family history 3 0
Sent by relative 2 0
Other reason 3 2
No answer 1 0
Total 66 8
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402 screenees receiving initial recommendation to per-
form further analysis/excision, we predict a detection of 
49 melanomas (12.2% of 402), 103 basal cell carcinomas 
(25.6% of 402), and 24 squamous cell carcinomas (6% of 
402). Given the morbidity, mortality, and the financial 
impact on health costs of skin cancer, we may assume that 
such a National Screening Day does have a positive im-
pact. All screening physicians in this campaign were vol-
unteers and did not receive any reimbursement for this, 
but assuming an average cost of screening (outside this 
campaign) per case in Switzerland of CHF 120 (EUR 
100), the costs for screening 2,782 individuals would be 
CHF 300,000 (EUR 280,000) (costs are hypothetical since 
the dermatologists have been participating in this cam-
paign without charge). Even though we are not able to 
formally prove it, we believe that this is an acceptable sum 
compared with the potential cost of only 5 missed mela-
nomas with consecutive dissemination and indication for 
therapy in their advanced stage using modern check-
point inhibitor therapies which annually cost up to more 
than EUR 100,000 per patient in Switzerland. Given the 
current costs of advanced-stage melanoma therapies, and 
those of primary and secondary prevention, the two goals 
of the campaign are warranted  [1] . While routine screen-
ing for early detection of skin cancer is not currently rec-
ommended, screening of individuals at increased risk for 
melanoma appears cost-effective  [2] .
 A total of 2,782 individuals were screened during this 
campaign. Of these, the number of individuals that re-
quired an intervention (either control or biopsy/exci-
sion), that agreed to participate, that we were able to con-
tact, and that ended up with a biopsy was 116 (see  Fig. 1 ). 
Out of these 116 histologies we were able to get the writ-
ten report in 66 (56.9%). Our absolute detection rate for 
melanoma of 0.29% is very similar to that of the large Eu-
romelanoma campaign published recently  [3] . The posi-
tive predictive value of 0.72 also compares favorably with 
those published previously  [3–5] . Although we had a rel-
atively small number of follow-ups, interestingly, 2 out of 
7 screenees (29%) with >100 nevi had a melanoma, where-
as only 6 out of 59 (10%) with <100 nevi were diagnosed 
with melanoma (data not shown), recapitulating the sig-
nificantly higher risk for melanoma in patients with high 
numbers of nevi  [6] .
 Skin cancers are ideal for secondary prevention, mean-
ing early diagnosis, because they are accessible to a simple 
visual inspection of the skin, and biopsy or excision can 
be performed very easily with a high chance of cure if the 
excision is performed early when tumor thickness is low. 
The detection of skin cancer during this screening cam-
paign is important and was our primary outcome mea-
sure. In addition, the media activity and publicity around 
the campaign has other important desired “side effects,” 
raising awareness for primary and secondary prevention 
of skin cancers. Unfortunately, it is methodologically not 
easy to measure this effect. 
 On the other hand, prevention campaigns might also 
create anxiety in screenees, and potential overdiagnosis/
overtreatment with consecutive psychological stress for 
the patient needs to be addressed  [7] .
 Over the last decades the incidence of melanoma has 
increased considerably  [8] . On the other hand, we have 
not observed an increased mortality in the same period 
(with only slight alterations in therapeutic interventions 
until the introduction of check-point inhibitors)  [9] . This 
raises the question of overdiagnosis, as in prostate and 
breast cancer  [7] . Overdiagnosis in this context describes 
histologically true melanomas (not false-positive diagno-
ses) which, however, would never develop into late-stage 
life-threatening melanomas.
 Overdiagnosed melanomas, therefore, are not false-
positive melanoma diagnoses, but as of today we have 
no prospective marker allowing us to separate overdiag-
nosed from potentially dangerous melanoma. It may, 
however, be important to consider this concept of over-
diagnosed melanoma when assessing the relatively high 
numbers of melanoma diagnoses in this and other studies 
 [3] , which reflects approximately a 16-fold increase in the 
population of screenees compared with the general popu-
lation.
 Skin cancer awareness and prevention campaigns have 
been performed for many years throughout the entire 
world. The Euromelanoma campaign exists since 1999  [5, 
10] . It has rapidly spread across the entire continent of 
Europe and is now active in 33 countries. So far more than 
450,000 people have received free skin screenings  [11] . 
The data are analyzed on a regular basis and are a very 
valuable source for such epidemiological research  [4, 5] . 
The data from prevention campaigns in Switzerland were 
analyzed and published in the past as well. According to 
the authors, in the last evaluation from 2003 a total of 108 
malignant lesions (21 melanomas) were detected in a to-
tal of 3,662 screened individuals (2.9%)  [12] . There have 
been efforts to measure the precise outcome of skin can-
cer prevention campaigns. Bulliard et al.  [13] asked skin 
cancer screening campaign participants, who required le-
sion excision, for their personal data and correlated this 
with the data of the cancer registry. This approach has, in 
our opinion, limitations because there was no informa-
tion on how many participants refused to participate, 
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how many ended up not seeing a physician, and how 
many of the treated lesions were not entered in the cancer 
registry database. From the 38 participants with suspect-
ed melanoma, they were able to trace 4 cases of histologi-
cally proven melanomas.
 The problem with the evaluations of many prevention 
campaigns in the past is that the diagnosis made by the 
screening physician was considered to be the true diagno-
sis  [12] . However, the problem of melanoma imitators 
and overdiagnosed melanomas is an ongoing clinical 
challenge for every dermatologist  [7, 14, 15] . In fact, this 
is a problem, because it is difficult to evaluate the efficacy 
and cost-effectiveness of this type of large public preven-
tion campaign without a precise solid outcome measure 
(e.g., number of histologically proven nonmelanoma skin 
cancers and melanomas per number of screenees during 
the campaign). Consistent with this, many public health 
decisions regarding prevention campaigns and budgets 
may have been taken in the past based on these “hypo-
thetical” diagnoses.
 Skin cancer screening of an unselected population is 
discussed controversially. The Cancer Council of Austra-
lia concludes that there is no evidence to recommend rou-
tine skin screening for skin cancer (Clinical Practice 
Guidelines for the Management of Melanoma 2008  [16] ) 
while the American Cancer Society supports this type of 
regular screening [reviewed in  17 ]. However, there is also 
recent evidence from the literature that this type of large-
scale population screening is able to reduce mortality 
from melanoma at least by half  [18–20] . This impressive 
reduction in mortality has also been shown in the pilot 
study of a small area of Germany (Schleswig-Holstein), 
whereas the follow-up study involving a much larger area 
was not able to confirm this  [21] .
 Currently there is no randomized controlled trial 
which formally proves that skin cancer screening does 
more benefit than harm, and in the lack of evidence this 
is discussed very controversially and very emotionally. 
The fact is that we still do not know  [22–24] . 
 Even though many efforts have been made in the past, 
there is a need for data analysis regarding public screen-
ing for skin cancer. A recent publication of a Cochrane 
review protocol on this topic outlines a review that may 
provide invaluable information on mortality data, over-
diagnosis, and psychological impact of screening activi-
ties for melanoma, focusing on randomized controlled 
trials comparing screening for melanoma with no screen-
ing, regardless of screening modality or setting  [25] .
 So, the important question here is whether we screen 
the right people, i.e., whether we really reach out to the 
risk population which we would otherwise miss. This an-
swer is probably no. In this campaign there was no prese-
lection of participants. Over the last couple of years, we 
observed the phenomenon that the same individuals 
would participate every year: in order to save money for 
a regular doctor’s appointment, many people would take 
advantage of the free skin cancer screening and do their 
annual checkups during the screening campaign. While 
we appreciate our returning screenees, we would prefer 
to find a way to screen a higher percentage of high-risk 
individuals that would otherwise not see a dermatologist. 
This could be achieved through a process of preselection, 
e.g., via telephone interview or online questioning of the 
potential screenee for risk situations such as number of 
nevi, age, profession, or sun exposure during childhood. 
Taken together, in our study, we made an effort to trace 
down the correct final histological diagnosis by contact-
ing screenees who agreed to be contacted. Despite this 
effort, we had an important dropout rate, as out of 402 
cases (excision/biopsy required), only 66 (16.4%) could 
finally be evaluated based on anonymized copies of the 
pathology report. We are currently investigating the rea-
sons for this low rate in order to optimize the return rate 
of information in future campaigns. This may in turn 
help in better preselecting the screening population for 
skin cancer in a setting of increasingly limited medico-
economic resources. So, in summary, we were not able to 
answer the question of whether we do the right thing. We 
believe that the only way to address this question would 
be via an international randomized controlled trial. In the 
meantime, until we have the results of this trial, we still 
have to carry out some prevention activities and raise the 
awareness of skin cancer in the population.
 Key Message 
 The costs of free screening programs compare favorably with 
the prevented potential therapeutic costs of late-stage melanoma. 
 Statement of Ethics 
 Ethics approval was not necessary according to Swiss Human 
Research Act.
 Disclosure Statement 
 The authors have no conflict of interest relevant to this study.
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